Stoke Therapeutics, Inc. (STOK) Financial Ratios
9 years of historical data (2017–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
43.18
+3% vs avg
5yr avg: 41.85
30Y Low41.8·High41.8
P/B Ratio
↑
5.51
↑+79% vs avg
5yr avg: 3.07
30Y Low1.5·High7.2
ROE
↑
-2.4%
↓+94% vs avg
5yr avg: -38.6%
30Y Low-61%·High-2%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
STOK Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Stoke Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis. On a free-cash-flow basis, the stock trades at 43.2x P/FCF, roughly in line with the 5-year average of 41.8x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.9B | $1.9B | $596M | $231M | $359M | $881M | $2.1B | $509M | — | — |
| Enterprise Value | $1.9B | $1.8B | $470M | $42M | $248M | $738M | $1.8B | $286M | — | — |
| P/E Ratio → | -273.25 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 10.52 | 10.19 | 16.30 | 26.36 | 28.94 | — | — | — | — | — |
| P/B Ratio | 5.51 | 5.33 | 2.60 | 1.45 | 1.94 | 4.05 | 7.25 | 2.27 | — | — |
| P/FCF | 43.18 | 41.85 | — | — | — | — | — | — | — | — |
| P/OCF | 42.55 | 41.23 | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
STOK EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 9.74 | 12.86 | 4.79 | 19.98 | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | 39.97 | — | — | — | — | — | — | — | — |
STOK Profitability
Margins and return-on-capital ratios measuring operating efficiency
Stoke Therapeutics, Inc. earns an operating margin of -11.2%. Operating margins have expanded from -1307.2% to -11.2% over the past 3 years, signaling improving operational efficiency. A negative ROE of -2.4% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — | — | — | — | — |
| Operating Margin | -11.2% | -11.2% | -277.3% | -1307.2% | -841.2% | — | — | — | — | — |
| Net Profit Margin | -3.7% | -3.7% | -243.4% | -1192.5% | -814.7% | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -2.4% | -2.4% | -45.8% | -60.8% | -50.2% | -34.1% | -20.5% | -19.6% | -24.1% | — |
| ROA | -2.0% | -2.0% | -35.6% | -43.2% | -40.8% | -32.0% | -19.8% | -19.2% | -22.8% | -227.9% |
| ROIC | -8.3% | -8.3% | -206.8% | -392.7% | -105.7% | -173.9% | -4437.6% | -3291.3% | — | — |
| ROCE | -7.0% | -7.0% | -47.3% | -54.4% | -46.8% | -33.9% | -20.8% | -21.6% | -24.6% | — |
STOK Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $84M exceeds total debt of $0, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.24 | -0.55 | -1.19 | -0.60 | -0.66 | -1.00 | -0.99 | -1.00 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | -1.88 | — | — | — | — | — | — | — | — |
| Interest Coverage | -1.50 | -1.50 | — | — | — | — | — | — | — | — |
Net cash position: cash ($84M) exceeds total debt ($0)
STOK Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Stoke Therapeutics, Inc.'s current ratio of 5.28x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 6.99x to 5.28x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.28 | 5.28 | 5.81 | 6.99 | 7.77 | 13.37 | 25.73 | 55.12 | 43.03 | 0.51 |
| Quick Ratio | 5.28 | 5.28 | 5.81 | 6.99 | 7.77 | 13.37 | 25.73 | 55.12 | 43.03 | 0.51 |
| Cash Ratio | 4.92 | 4.92 | 5.41 | 6.53 | 7.31 | 12.83 | 25.15 | 54.25 | 42.72 | 0.48 |
| Asset Turnover | — | 0.44 | 0.13 | 0.04 | 0.05 | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 15.65 | 6.99 | 2.66 | 17.30 | — | — | — | — | — |
STOK Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Stoke Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | 2.3% | 2.4% | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $59M | $54M | $44M | $39M | $37M | $33M | $18M | $24M | $24M |
Peer Comparison
Compare STOK with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 STOKYou | $2B | -273.3 | — | 43.2 | 100.0% | -11.2% | -2.4% | -8.3% | — |
 ACAD | $4B | 9.9 | 26.9 | 36.7 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 PRAX | $10B | -24.7 | — | — | — | — | -45.8% | -65.0% | — |
 ARVN | $652M | -8.0 | — | — | 98.0% | -43.8% | -16.2% | -22.4% | — |
 IONS | $13B | -31.9 | — | — | 98.3% | -40.5% | -70.7% | -12.8% | — |
 SRPT | $2B | -2.9 | — | — | 59.9% | -29.9% | -53.5% | -31.4% | — |
 ALNY | $39B | 127.0 | 70.2 | 84.8 | 81.8% | 13.5% | 73.3% | 33.4% | 2.3 |
 ARWR | $11B | -6389.3 | 90.4 | 69.6 | 97.1% | 11.9% | -0.5% | 9.3% | 3.0 |
 NTLA | $2B | -3.6 | — | — | 76.5% | -651.7% | -53.5% | -44.0% | — |
 BEAM | $3B | -38.9 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 ILMN | $21B | 25.5 | 19.6 | 22.6 | 66.7% | 19.9% | 33.4% | 16.8% | 2.3 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 9 years · Updated daily
See STOK's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs STOK Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare STOK vs ACAD
Side-by-side business, growth, and profitability comparison vs ACADIA Pharmaceuticals Inc..
Start ComparisonSTOK — Frequently Asked Questions
Quick answers to the most common questions about buying STOK stock.
What is Stoke Therapeutics, Inc.'s P/E ratio?
Stoke Therapeutics, Inc.'s current P/E ratio is -273.3x. This places it at the 50th percentile of its historical range.
What is Stoke Therapeutics, Inc.'s ROE?
Stoke Therapeutics, Inc.'s return on equity (ROE) is -2.4%. The historical average is -32.2%.
Is STOK stock overvalued?
Based on historical data, Stoke Therapeutics, Inc. is trading at a P/E of -273.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Stoke Therapeutics, Inc.'s profit margins?
Stoke Therapeutics, Inc. has 100.0% gross margin and -11.2% operating margin.